Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALLO 
Allogene Therapeutics Inc (ALLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ALLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.56
1 Year Target Price $7.56
| 8 | Strong Buy |
| 4 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.55% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 250.73M USD | Price to earnings Ratio - | 1Y Target Price 7.56 |
Price to earnings Ratio - | 1Y Target Price 7.56 | ||
Volume (30-day avg) 14 | Beta 0.36 | 52 Weeks Range 0.86 - 3.78 | Updated Date 09/12/2025 |
52 Weeks Range 0.86 - 3.78 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.98% | Return on Equity (TTM) -55.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 65721803 | Price to Sales(TTM) 11631.14 |
Enterprise Value 65721803 | Price to Sales(TTM) 11631.14 | ||
Enterprise Value to Revenue 3859.62 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 221880992 | Shares Floating 164975201 |
Shares Outstanding 221880992 | Shares Floating 164975201 | ||
Percent Insiders 17.45 | Percent Institutions 74.09 |
Upturn AI SWOT
Allogene Therapeutics Inc
Company Overview
History and Background
Allogene Therapeutics, Inc. was founded in 2018, emerging from Pfizer's cell therapy programs. It focuses on developing allogeneic CAR T-cell therapies for cancer. A key milestone was its IPO in 2018. Its evolution has centered on advancing its AlloCAR T platform.
Core Business Areas
- AlloCAR T Development: Allogene's primary focus is developing allogeneic CAR T-cell therapies, which are off-the-shelf cell therapies derived from healthy donors and engineered to target specific cancer antigens.
Leadership and Structure
David Chang serves as the CEO. The company has a typical biotech organizational structure with research, development, clinical operations, and commercial functions. The Board of Directors includes experienced biotech executives and investors.
Top Products and Market Share
Key Offerings
- Orelabrutinib: Was an oral Bruton's tyrosine kinase (BTK) inhibitor being developed for hematological malignancies and autoimmune diseases. Clinical trials were discontinued, so there is no market share or revenue. Competitors include Imbruvica (ibrutinib) from AbbVie and Janssen, and Calquence (acalabrutinib) from AstraZeneca.
- AlloCAR T platform: Allogene's investigational allogeneic CAR T-cell therapy candidates target various hematological malignancies. These therapies are in clinical development and not yet approved for commercial use, therefore there is no market share or revenue associated with them. The entire field is highly competitive, with leaders like Kite Pharma (GILD), Novartis (NOVN), and numerous smaller biotechs all working on various forms of cell therapies.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly evolving, with significant advancements in CAR T-cell therapy and gene editing technologies. The market is characterized by high growth potential, intense competition, and complex regulatory pathways.
Positioning
Allogene aims to be a leader in allogeneic CAR T-cell therapy, offering off-the-shelf products to address the limitations of autologous CAR T-cell therapy (patient specific). Its competitive advantage lies in its AlloCAR T platform. However, clinical setbacks have significantly impacted its positioning.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to reach billions of dollars, with varying projections depending on the source and assumptions. Allogene's position in the TAM is currently limited due to the early stage of its pipeline and the failures in its clinical trials. The current market capitalization reflects some of the TAM value, but not a very large share at this time.
Upturn SWOT Analysis
Strengths
- AlloCAR T platform technology
- Experienced leadership team
- Established manufacturing capabilities
Weaknesses
- Clinical trial setbacks and program discontinuations
- High cash burn rate
- Reliance on clinical trial success for value creation
- Regulatory uncertainty surrounding allogeneic cell therapies
- Dependence on Cellectis' TALEN gene editing technology
Opportunities
- Potential for partnerships and collaborations
- Expansion of pipeline into new cancer indications
- Advancements in manufacturing technologies to reduce costs
- Positive clinical data from ongoing trials
- Regulatory approval of AlloCAR T therapies
Threats
- Competition from autologous CAR T-cell therapies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property disputes
- Adverse events associated with AlloCAR T therapies
- Limited durability of response
Competitors and Market Share
Key Competitors
- GILD
- NOVN
- BMY
- CRSP
Competitive Landscape
Allogene faces intense competition from established players in autologous CAR T-cell therapy and emerging companies in allogeneic cell therapy. Its advantages include its AlloCAR T platform and manufacturing capabilities. Its disadvantages include clinical trial setbacks and program discontinuations.
Growth Trajectory and Initiatives
Historical Growth: Allogene's historical growth has been characterized by rapid expansion in R&D activities and infrastructure, offset by the share price decrease due to program failures.
Future Projections: Future growth projections are highly uncertain and contingent on positive clinical trial data and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives have focused on streamlining operations, and attempting to advance the remaining AlloCAR T programs.
Summary
Allogene Therapeutics faces significant challenges following clinical trial setbacks. While their AlloCAR T platform holds promise, the company needs to demonstrate clinical efficacy to restore investor confidence. The recent program discontinuations highlight the risks inherent in biotech development. Success hinges on future clinical trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates and is not financial advice. Clinical trial outcomes and regulatory approvals are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allogene Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Dr. David D. Chang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 226 | Website https://allogene.com |
Full time employees 226 | Website https://allogene.com | ||
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.